|
|
(HealthNewsDigest.com) – It is the first and only low-level laser to receive FDA clearance for onychomycosis, nail fungus. The Lunul a is a portable laser device from Erchonia Corporation that targets the area infected with this new technology and increases the amount of clear nail for patients.
Nail fungal infections affects 7-12% of the general population with an estimated 35 million seeking some type of treatment.
Onychomycosis accounts for up to 30% of all skin infections.
Previously, treatment for nail fungus often included called for ineffective, over-the-counter topical creams or prescription oral antifungal medication, which can increase the potential for liver toxicity issues.
In a clinical trial, 67 percent of patients met the success criteria of three millimeters of clear nail growth. By six months after the initial treatment, these patients average more than five millimeters of new growth. During the study, patients between 18 and 70 years old received treatments once a week for four weeks.
“Lunula is the future of treating onychomycosis,” said Dr. Kerry Zang, foun der of the Arizona Institute of Footcare. “The results seen in the clinical trial are spectacular and we are eager to provide Americans with the opportunity to treat this nail fungus with an effective product.”
Zang and Dr. Robert Sullivan lead the research behind Lunula.
“Nail fungus is a big problem and the toxicity of the available drugs is almost as bad,” said Dr. Sullivan. “Lunula gives doctors a viable treatment option: no blood tests, no pain and no mess.”
For more information: www.lunula.com
Founded in 1996, Erchonia Corporation is the world leader in low-level laser technology. The company created the low-level laser category in 2002 when it received an FDA 510(k) market clearance for low-level lasers. Erchonia was the first company to receive this FDA 510(k) distinction. www.erchonia.com
# # #